Rockville, MD. Rise Therapeutics today announced that the U.S. Patent Trademark Office issued a U.S. patent, No. 9,931,390, entitled “Recombinant Lactococcus Lactis expressing Escherichia Coli Colonization Factor Antigen I (CFA/I) Fimbriae and Their Methods of Use.” The patent covers a first-in-class design related to a platform approach to deliver targeted protein therapies orally. This approach can be used to treat a variety of disease indications.
Rockville, MD. Rise Therapeutics announced today they received their first Small Business Innovation Research (SBIR) Grant from the National of the National Institute of Health (NIH) for their application, “A Novel Probiotic for Preventing and Treating Clostridium Difficile Pathogenesis.” This award signals a significant milestone for Rise Therapeutics and provides a solid foundation for the future of the company.
Rockville, MD. Rise Therapeutics, a biotechnology company that develops microbiome-based immunological drugs using a unique and proprietary oral biologics delivery platform, announced today that it received seed funding from Maryland Technology Development Corporation (TEDCO). TEDCO is an early-stage funding hub that supports entrepreneurs and drives technology transfer and commercialization in the state of Maryland.
The Maryland Technology Development Corporation (TEDCO) announced today that six companies received a total of $800,000 in seed funding.
“At TEDCO, our mission is to foster entrepreneurship and innovation across all regions of the state and we aim to discover, invest in and build great companies that grow, stay and last in Maryland,” stated TEDCO CEO George Davis. “TEDCO helps entrepreneurs bring innovation to market by being the connective tissue to all available assets in the ecosystem, including capital and business development tools.”
Virtici, LLC announced today the spin-out of a new drug development company, Rise Therapeutics, which is focused on developing microbiome-based, immunological therapies. To form the spin-out, Rise obtained key microbiome-related intellectual property and technologies incubated at Virtici to support the development of first-in-class, orally-delivered, biological medicines.